Rifaximin for the treatment of diarrhoea-predominant irritable bowel syndrome

Lucrezia Laterza, Gianluca Ianiro, Iolanda Scoleri, Rosario Landi, Franco Scaldaferri, Eleonora Gaetani, Mariachiara Campanale, Antonio Gasbarrini

Risultato della ricerca: Contributo in rivistaArticolo in rivista

12 Citazioni (Scopus)


Rifaximin is a non-absorbable, semisynthetic antibiotic that acts as an inhibitor of bacterial RNA synthesis, with a broad spectrum of antibacterial activity. Due to its poor absorption, rifaximin has an increased exposure to the intestine, thus it is suitable for the treatment of many gastrointestinal (GI) diseases. In irritable bowel syndrome (IBS) pathogenesis, gut microbiota impairment may play a major role. The possibility of modulating intestinal bacteria using antibiotics, in particular, rifaximin, has been demonstrated to improve IBS symptoms in non-constipation subtypes of IBS.
Lingua originaleEnglish
pagine (da-a)607-615
Numero di pagine9
RivistaExpert Opinion on Pharmacotherapy
Stato di pubblicazionePubblicato - 2015


  • Animals
  • Anti-Bacterial Agents
  • Diarrhea
  • Drug Interactions
  • Drug Resistance, Bacterial
  • Humans
  • Irritable Bowel Syndrome
  • Rifamycins
  • antibiotics
  • gut microbiota
  • irritable bowel syndrome
  • pharmacokinetic
  • rifaximin


Entra nei temi di ricerca di 'Rifaximin for the treatment of diarrhoea-predominant irritable bowel syndrome'. Insieme formano una fingerprint unica.

Cita questo